Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000049513 | SCV000793463 | likely pathogenic | Non-ketotic hyperglycinemia | 2017-08-16 | criteria provided, single submitter | clinical testing | |
Integrated Genetics/Laboratory Corporation of America | RCV000049513 | SCV000919469 | pathogenic | Non-ketotic hyperglycinemia | 2018-09-28 | criteria provided, single submitter | clinical testing | Variant summary: GLDC c.806C>T (p.Thr269Met) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 246244 control chromosomes. c.806C>T has been reported in the literature in multiple individuals affected with Glycine Encephalopathy (Non-Ketotic Hyperglycinemia) both as a compound heterozygous and homozygous allele (Conter_2006, Coughlin_2017). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on residual enzyme activity, where <10% of normal activity was observed in vitro (Swanson_2015). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Invitae | RCV000049513 | SCV000945814 | pathogenic | Non-ketotic hyperglycinemia | 2019-11-20 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine with methionine at codon 269 of the GLDC protein (p.Thr269Met). The threonine residue is highly conserved and there is a moderate physicochemical difference between threonine and methionine. This variant is present in population databases (rs386833587, ExAC 0.02%). This variant has been observed to be homozygous and in combination with another GLDC variant in individuals affected with nonketotic hyperglycinemia (PMID: 16601880, 16450403, 27362913). ClinVar contains an entry for this variant (Variation ID: 56104). This variant has been reported to affect GLDC protein function (PMID: 26179960). For these reasons, this variant has been classified as Pathogenic. |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049513 | SCV000081949 | probable-pathogenic | Non-ketotic hyperglycinemia | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. | |
Natera, |
RCV000049513 | SCV001458165 | pathogenic | Non-ketotic hyperglycinemia | 2020-09-16 | no assertion criteria provided | clinical testing |